시장보고서
상품코드
1172560

세계의 두경부암 치료제 시장 : 시장 규모, 시장 점유율, 동향 분석, 기회, 예측, 유형별, 치료 유형별, 투여 경로별, 최종 사용자별, 지역별(2018-2028년)

Head and Neck Cancer Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018-2028, Segmented By Type ; Treatment Type ; Route of Administration ; By End-User ; Region

발행일: | 리서치사: Blueweave Consulting | 페이지 정보: 영문 254 Pages | 배송안내 : 2-3일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

세계의 두경부암 치료제 시장 규모는 2021년 11억 달러에서 2028년 약 26억 달러에 이르고, 예측 기간 동안 12.6%의 CAGR로 성장할 것으로 예측됩니다. 바이오시밀러와 조기 진단법 사용 증가, 적극적인 의료 개혁은 시장 성장을 촉진하고 있습니다.

세계의 두경부암 치료제(Head and Neck Cancer Therapeutics) 시장을 조사했으며 시장 주요 요약, 시장 분석, 기업 프로필 등 포괄적인 정보를 제공합니다.

목차

제1장 조사 틀

제2장 주요 요약

제3장 세계의 두경부암 치료제 시장 인사이트

  • 업계 밸류체인 분석
  • DROC 분석
    • 촉진 요인
      • 바이오시밀러 사용 증가
      • 조기 진단법 상승
      • 긍정적인 건강 관리 개혁
    • 억제 요인
      • 중대한 약 부작용
      • 기타
    • 기회
      • 두경부암 치료 병용 요법 수요 증가
      • 기타
    • 과제
      • 높은 치료비
      • 기타
  • 기술 진보/최근 개발
  • 규제 틀
  • 포터의 5가지 경쟁요인 분석
    • 공급기업 협상력
    • 구매자 협상력
    • 신규 참가업체 위협
    • 대체품 위협
    • 경쟁 심각성

제4장 세계의 두경부암 치료 시장 주요 요약

  • 시장 규모와 예측(2018-2028년) : 금액별
    • 금액별(100만 달러)
  • 시장 점유율과 예측
    • 유형별
      • 진단
      • 치료
    • 치료 유형별
      • 적응증별
    • 투여 경로별
      • 주사
      • 경구
    • 최종 사용자별
      • 병원
      • 전문 클리닉
      • 외래 수술 센터
      • 기타
    • 지역별
      • 북미
      • 유럽
      • 아시아태평양
      • 라틴아메리카
      • 중동과 아프리카

제5장 북미 두경부암 치료제 시장

제6장 유럽 두경부암 치료제 시장

제7장 아시아태평양 지역 두경부암 치료제 시장

제8장 라틴아메리카 두경부암 치료제 시장

제9장 중동 및 아프리카 두경부암 치료제 시장

제10장 경쟁 상황

  • 주요 기업과 그 제품 목록
  • 시장 점유율 분석(2021년)
  • 경쟁 벤치마킹 : 조작 파라미터별
  • 주요 전략 전개(합병, 인수, 파트너십 등)

제11장 세계의 두경부암 치료제 시장 COVID-19 영향

제12장 기업 프로필(기업 주요 요약, 재무 매트릭스, 경쟁 상황, 주요 인재, 주요 경쟁, 연락처, SWOT 및 전략 전망)**

  • Pfizer INC
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Limited
  • Intas Pharmaceuticals Ltd
  • Glaxosmithkline PLC
  • Novartis International AG
  • Sanofi
  • Bayer AG
  • Hoffmann-LA Roche AG
  • Merck& co., INC
  • Astrazenica PLC
  • Teva Pharmaceutical Industries Ltd.
  • 기타

제13장 주요 전략 권장사항

제14장 조사 방법

참고 : 최종 납품물에서 위 이외 회사 재무 정보는 데이터를 사용할 수 있는 즉시 제공됩니다.

최종 납품물에서 세분화 및 기업은 상세한 보충 정보에 따라 변경될 수 있습니다.

NJH 22.12.23

Global Head and Neck Cancer Therapeutics Market to Grow at a CAGR of 12.6% during Forecast Period.

Global Head and Neck Cancer Therapeutics Market is growing at a high CAGR because of the rising use of biosimilars and early diagnostic methods as well as positive healthcare reforms.

A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Head and Neck Cancer Therapeutics Market was worth USD 1.1 billion in the year 2021. The market is projected to grow at a CAGR of 12.6% from 2022-2028 (forecast period), earning revenues of around USD 2.6 billion by the end of 2028. The Global Head and Neck Cancer Therapeutics Market is booming because of the rising demand for consumer electronic items like smartphones, televisions, and digital cameras, as well as the increased manufacturing of electric cars. In addition, rising demand for IoT devices is emerging as a significant driver of market expansion. However, high dependence on other countries for semiconductor chip imports may act as a huge restraining factor for market growth.

Increased demand for a combination treatment for head and neck cancer care

Increases in the prevalence of specific diseases and the availability of better healthcare thanks to public and private sector initiatives are all expected to propel the industry forward in the next years. The global market for head and neck cancer treatments is growing as a result of several factors, including the rising incidence of this disease worldwide, the rising preference for multimodal approaches to care, and the rising emphasis on research and development to identify the most effective clinical therapy.

In addition, an increase in risk factors such as alcohol, cigarette smoking, and tobacco use is anticipated to contribute to the growing worldwide need for head and neck cancer treatments.

Challenge

High treatment costs

Market growth is anticipated to be stymied by the high expenses associated with the treatment plan, the unfavorable reactions of alternative treatment alternatives, the dearth of insurance services, and the inadequate healthcare system in low- and middle-income countries. Moreover, this patient population faces major issues, such as morbidity and bad quality of life, as a direct result of the incapacitating impact of normal healthcare practices.

Segmental Coverage

Global Head and Neck Cancer Therapeutics Market - By End-User

On the basis of end-user segmentation, the Global Head and Neck Cancer Therapeutics Market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others. Whereby hospitals and specialty clinics take a sizable amount in market share. Due to simple access to medications and inexpensive distribution costs, producers are very likely to distribute their goods, which explains the dominance. According to the Drug Channels Institute's research, the top five specialty pharmacies in the globe in 2021 were Humana specialty pharmacy, Accredo, CVS Specialty, Walgreens stores, and Optum specialty pharmacy.

Global Head and Neck Cancer Therapeutics Market - By Region

The global market for head and neck cancer therapies is divided into five primary regions based on geographical presence. These regions are North America, Europe, The Asia Pacific, Latin America, the Middle East, and Africa. The high frequency of HPV-induced malignancies and the high smoking rate in North America will continue to provide the region with a dominant position in the worldwide head and neck cancer treatment market. It is anticipated that Europe will hold the second biggest market share in the global market for head and neck cancer therapies.

Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) that produced the 2019 coronavirus disease (COVID-19) pandemic poses a unique challenge to the world's healthcare infrastructure, including the Global Head and Neck Cancer Therapeutics Market. Standardized treatment for cancer patients was a part of this difficulty. During this time, most in-hospital cancer treatments were discontinued, and only select patients were given radiation therapy with the goal of curing them in accordance with strict protocols to ensure their safety, thereby leading to disturbances and inconveniences in the Global Head and Neck Cancer Therapeutics Market.

Competitive Landscape

Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis International AG, Sanofi, Bayer AG, Hoffmann-LA Roche AG, Merck & co., INC., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., and Other Prominent Players are active in this industry. AstraZeneca and Pfizer are expected to benefit from the approval of Imfinzi and Bavencio during the projection period. Sanofi and Eli Lilly have been affected by expiring patents and biosimilar medicine competition. Several market participants are expected to collaborate on meeting unmet requirements, discovering novel targets, and developing stronger treatment pipelines.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Head and Neck Cancer Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Head and Neck Cancer Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Head and Neck Cancer Therapeutics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Biosimilar Use
      • 3.2.1.2. Rise in early Diagnostic Methods
      • 3.2.1.3. Positive Healthcare Reforms
    • 3.2.2. Restraints
      • 3.2.2.1. Frequent failure at the end of the process, Substantial medication adverse effects are a fact of life
      • 3.2.2.2. Others
    • 3.2.3. Opportunities
      • 3.2.3.1. Increased demand for a combination treatment for head and neck cancer care
      • 3.2.3.2. Others
    • 3.2.4. Challenges
      • 3.2.4.1. High Treatment Cost
      • 3.2.4.2. Others
  • 3.3. Technological Advancement/Recent Development
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Head and Neck Cancer Therapeutics Market Overview

  • 4.1. Market Size & Forecast by Value, 2018-2028
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Diagnostic Method
      • 4.2.1.1.1. Biopsy
      • 4.2.1.1.2. Imaging
      • 4.2.1.1.3. Endoscopy
      • 4.2.1.1.4. Others
      • 4.2.1.2. Treatment
      • 4.2.1.2.1. Surgery
      • 4.2.1.2.2. Radiation Therapy
      • 4.2.1.2.3. Chemotherapy
      • 4.2.1.2.4. Immunotherapy
      • 4.2.1.2.5. Targeted Therapy
    • 4.2.2. By Treatment Type
      • 4.2.2.1. By Disease Indication
      • 4.2.2.1.1. Lip and Oral Cavity Cancer
      • 4.2.2.1.2. Laryngeal Cancer
      • 4.2.2.1.3. Oropharyngeal Cancer
      • 4.2.2.1.4. Salivary Gland Cancer
      • 4.2.2.1.5. Nasopharyngeal Cancer
      • 4.2.2.1.6. Hypopharyngeal Cancer
    • 4.2.3. By Route of Administration
      • 4.2.3.1. Injectable
      • 4.2.3.2. Oral
    • 4.2.4. By End-User
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Specialty Clinics
      • 4.2.4.3. Ambulatory Surgical Centers
      • 4.2.4.4. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. The Asia Pacific
      • 4.2.5.4. Latin America
      • 4.2.5.5. The Middle East and Africa

5. North America Head and Neck Cancer Therapeutics Market

  • 5.1. Market Size & Forecast by Value, 2018-2028
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment Type
    • 5.2.3. By Route of Administration
    • 5.2.4. By End-User
    • 5.2.5. By Country
      • 5.2.5.1. United Type
      • 5.2.5.2. Canada

6. Europe Head and Neck Cancer Therapeutics Market

  • 6.1. Market Size & Forecast by Value, 2018-2028
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By End-User
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.2. United Kingdom
      • 6.2.5.3. Italy
      • 6.2.5.4. France
      • 6.2.5.5. Spain
      • 6.2.5.6. Rest of Europe

7. The Asia Pacific Head and Neck Cancer Therapeutics Market

  • 7.1. Market Size & Forecast by Value, 2018-2028
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By End-User
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.2. India
      • 7.2.5.3. Japan
      • 7.2.5.4. South Korea
      • 7.2.5.5. Australia
      • 7.2.5.6. Indonesia
      • 7.2.5.7. Singapore
      • 7.2.5.8. Malaysia
      • 7.2.5.9. Rest of Asia Pacific

8. Latin America Head and Neck Cancer Therapeutics Market

  • 8.1. Market Size & Forecast by Value, 2018-2028
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By End-User
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.2. Mexico
      • 8.2.5.3. Argentina
      • 8.2.5.4. Rest of Latin America

9. The Middle East & Africa Head and Neck Cancer Therapeutics Market

  • 9.1. Market Size & Forecast by Value, 2018-2028
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.2. UAE
      • 9.2.5.3. South Africa
      • 9.2.5.4. Iran
      • 9.2.5.5. Nigeria
      • 9.2.5.6. Egypt
      • 9.2.5.7. Turkey
      • 9.2.5.8. Rest of Middle East & Africa

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Market Share Analysis, 2021
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Head and Neck Cancer Therapeutics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, SWOT, and Strategic Outlook) **

  • 12.1. Pfizer INC
  • 12.2. Eli Lilly and Company
  • 12.3. Sun Pharmaceutical Industries Limited
  • 12.4. Intas Pharmaceuticals Ltd
  • 12.5. Glaxosmithkline PLC
  • 12.6. Novartis International AG
  • 12.7. Sanofi
  • 12.8. Bayer AG
  • 12.9. Hoffmann-LA Roche AG
  • 12.10. Merck & co., INC
  • 12.11. Astrazenica PLC
  • 12.12. Teva Pharmaceutical Industries Ltd.
  • 12.13. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents
  • 14.5. Assumptions & Limitations

Note: Financial in information in case of non-listed companies will be provided as per availability

The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제